XOMA

XOMA plays a unique role in helping biotech companies achieve their goal of improving human health. We do this by acquiring the economic rights to future potential milestone and royalty payments associated with partnered pre-commercial clinical candidates. In return the seller receives non-dilutive, non-recourse funding to advance their internal drug candidate(s).

We encourage holders of royalty licenses to pre-commercial therapeutic assets that are in active development to contact us regarding our interest in acquiring that license. For inquiries regarding share ownership, transfer, etc., please contact XOMA's transfer agent:. An AST shareholder services representative can be reached at 800-937-5449 or 718-921-8124 between the hours of 8 a.m. and 8 p.m. Eastern Time, Monday through Friday.

This dynamic requires the biotech company to identify sources of capital to fund clinical development and achieve their goal of curing a disease. One source of capital is licensing a lead product to a pharmaceutical company. The biotech can then use that capital to develop other assets. Where companies find the most challenging financial environment is during the long stretches of time while they are waiting for a clinical study to complete and read-out.As many investors in pre-commercial biotechs focus on these binary inflection events, raising money during those periods through public offerings can be very challenging and expensive.

We acquire future potential milestone and royalty rights associated with pre-commercial therapeutic assets that are being developed by global pharmaceutical and biotech companies. We understand the value of milestone and royalty rights. For biotech companies, monetizing these assets results in an infusion of non-dilutive, non-recourse capital to fund operations and pursue clinical goals.